Treat to target in #lupus - difficult for many reasons. Also may be too much of a restrictive strategy. @Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n

Many drugs in the horizon for #lupus @Lupusreference lecture #EULAR2024 Loved the timeline of all major drug -phase 2 and 3 drugs. Need for new strategies in Lupus – outcomes and survival is plateauing! @RheumNow https://t.co/Ue239woQJr

Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session. Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5

Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon. Looking forward to playing with this. #LLMs #ChatGPT More to come. @RheumNow https://t.co/mGXG6A85Hx

Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024 We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR

@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn

Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls. Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids) @RheumNow https://t.co/Fz1dZUVomF

💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6